Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12565150 | 0.92 | PRCP (0.45) | PRCPHPGDSTMEM97SIGMAR1KCNH2 | |
| SCHEMBL10076571 | 0.86 | PRCP (0.59) | PRCPHPGDSKCNH2OPRM1OPRD1 | |
| SCHEMBL12302210 | 0.85 | PRCP (0.51) | PRCPHPGDSTMEM97SIGMAR1 | |
| SCHEMBL7604141 | 0.83 | PRCP (0.55) | PRCPHPGDSKCNH2OPRM1OPRD1 | |
| SCHEMBL6126817 | 0.83 | PRCP (0.55) | PRCPHPGDSKCNH2OPRM1OPRD1 | |
| SCHEMBL691476 | 0.82 | HPGDS (0.61) | PRCPHPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL13501764 | 0.82 | HPGDS (0.61) | PRCPHPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL691477 | 0.82 | HPGDS (0.61) | PRCPHPGDSKCNH2CYP3A4CYP2C9 | |
| SCHEMBL10254627 | 0.82 | PRCP (0.53) | PRCPHPGDSKCNH2OPRM1OPRD1 | |
| SCHEMBL12599425 | 0.82 | PRCP (0.53) | PRCPHPGDSKCNH2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | PRCP 989/4885HPGDS 3648/4885TMEM97 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.